Inovio Pharmaceuticals, Inc. (INO)
1.64
-0.07
(-4.09%)
USD |
NASDAQ |
Nov 20, 10:21
Inovio Pharmaceuticals Free Cash Flow : -74.41M for Sept. 30, 2026
Free Cash Flow Chart
Historical Free Cash Flow Data
| Date | Value |
|---|---|
| September 30, 2026 | -74.41M |
| June 30, 2026 | -80.78M |
| March 31, 2026 | -83.57M |
| December 31, 2025 | -88.92M |
| September 30, 2025 | -89.08M |
| June 30, 2025 | -94.88M |
| March 31, 2025 | -102.70M |
| December 31, 2024 | -104.56M |
| September 30, 2024 | -111.18M |
| June 30, 2024 | -112.84M |
| March 31, 2024 | -116.52M |
| December 31, 2023 | -124.69M |
| September 30, 2023 | -134.92M |
| June 30, 2023 | -173.36M |
| March 31, 2023 | -192.26M |
| December 31, 2022 | -217.18M |
| September 30, 2022 | -219.21M |
| June 30, 2022 | -198.32M |
| March 31, 2022 | -225.74M |
| December 31, 2021 | -216.94M |
| September 30, 2021 | -230.58M |
| June 30, 2021 | -258.46M |
| March 31, 2021 | -206.98M |
| December 31, 2020 | -179.50M |
| September 30, 2020 | -141.17M |
| Date | Value |
|---|---|
| June 30, 2020 | -94.50M |
| March 31, 2020 | -91.32M |
| December 31, 2019 | -98.84M |
| September 30, 2019 | -102.61M |
| June 30, 2019 | -99.54M |
| March 31, 2019 | -95.02M |
| December 31, 2018 | -75.64M |
| September 30, 2018 | -72.84M |
| June 30, 2018 | -68.94M |
| March 31, 2018 | -71.21M |
| December 31, 2017 | -73.50M |
| September 30, 2017 | -73.65M |
| June 30, 2017 | -71.86M |
| March 31, 2017 | -66.09M |
| December 31, 2016 | -66.49M |
| September 30, 2016 | -59.12M |
| June 30, 2016 | -25.36M |
| March 31, 2016 | -19.05M |
| December 31, 2015 | -15.22M |
| September 30, 2015 | -15.97M |
| June 30, 2015 | -38.97M |
| March 31, 2015 | -38.16M |
| December 31, 2014 | -31.30M |
| September 30, 2014 | -22.01M |
| June 30, 2014 | -19.53M |
Free Cash Flow Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Free Cash Flow Benchmarks
| Precigen, Inc. | -74.32M |
| Arrowhead Pharmaceuticals, Inc. | -283.94M |
| Ionis Pharmaceuticals, Inc. | -622.77M |
| Nektar Therapeutics | -257.48M |
| Rigel Pharmaceuticals, Inc. | 19.37M |
Free Cash Flow Related Metrics
| Cash from Operations (Quarterly) | -15.27M |
| Cash from Investing (Quarterly) | 3.724M |
| Cash from Financing (Quarterly) | 26.99M |
| Free Cash Flow Per Share (Quarterly) | -0.1549 |
| Free Cash Flow to Equity (Quarterly) | -14.55M |
| Free Cash Flow to Firm (Quarterly) | -15.27M |
| Free Cash Flow Yield | -41.18% |